Xadago/safinamide Cost, Side effects, Dosage, Uses for Parkinson’s disease. The FDA granted approval of Xadago to Newron Pharmaceuticals.
US FDA approved a new drug that contains active ingredient safinamide as an adjuvant therapy for the treatment of  Parkinson disease. According to FDA this drug should be used as add on therapy when other Parkinson medications such levodopa or carbidopa does not provide adequate response or symptoms of Parkinson may get worse (off episodes).
Parkinson disease (PD) is a characterized as degenerative disorders that affects motor functions as well as activities related to central nervous system. Disease onset is slow but it remains lifetime and symptoms of parkinson disease may become severe with the passage of time. In advance stages, this disease may lead to further irreversible changes like dementia. Most common manifestations of this disease are mood changes, cognitive impairment, speech difficulty, tremors, rigidity, difficulty in movements etc. The exact underlying cause this disease is still unclear but many scientist
believed that genetic predisposition and certain environment factors play important in role in pathogenesis of Parkinson disease.
Xadago has dual mechanism of action based to increase concentration of dopamine on pre-synaptic cleft by reversible  inhibition of MAO-B and of dopamine uptake and creases the induction of glutamate release. End point of all Parkinson based medications is inducing the release of dopamine on pre-synaptic cleft, reducing the degradation of dopamine neurotransmitter or inhibition of dopamine re-uptake.
According to data obtained from clinical trials of Xadago/safinamide side effects are categorized as common side effects and less common side effects.
US FDA approved a new drug that contains active ingredient safinamide as an adjuvant therapy for the treatment of  Parkinson disease. According to FDA this drug should be used as add on therapy when other Parkinson medications such levodopa or carbidopa does not provide adequate response or symptoms of Parkinson may get worse (off episodes).
Parkinson disease (PD) is a characterized as degenerative disorders that affects motor functions as well as activities related to central nervous system. Disease onset is slow but it remains lifetime and symptoms of parkinson disease may become severe with the passage of time. In advance stages, this disease may lead to further irreversible changes like dementia. Most common manifestations of this disease are mood changes, cognitive impairment, speech difficulty, tremors, rigidity, difficulty in movements etc. The exact underlying cause this disease is still unclear but many scientist
believed that genetic predisposition and certain environment factors play important in role in pathogenesis of Parkinson disease.
Xadago has dual mechanism of action based to increase concentration of dopamine on pre-synaptic cleft by reversible  inhibition of MAO-B and of dopamine uptake and creases the induction of glutamate release. End point of all Parkinson based medications is inducing the release of dopamine on pre-synaptic cleft, reducing the degradation of dopamine neurotransmitter or inhibition of dopamine re-uptake.
Xadago/safinamide Side effects
According to data obtained from clinical trials of Xadago/safinamide side effects are categorized as common side effects and less common side effects.
Common Side effects
- NauseaÂ
- Vomiting
- Difficulty in sleeping
- InsomniaÂ
- Uncontrolled movements
Less common Side effects
- Hyperprexia
- hypertension
- serotonin syndrome
- agitation
- retinal problems
Xadago/safinamide Uses
FDA approved Xadago for the treatment of Parkinson disease in patients who experience "off episode" e.g symptoms are getting worse even after using Parkinson base medications like dopa drugs. In that case Xadago is helpful and patient can take this drug as add on therapy.
0 Comments
For comments please reply here.......